# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: k100489   
B. Purpose for Submission: New device   
C. Manufacturer and Instrument Name: Beckman Coulter, Inc., $\mathrm { D x H } ^ { \mathrm { T M } } 3 0 0$ and DxH™ 300C COULTER $^ \mathrm { \textregistered }$ Cellular Analysis Systems   
D. Type of Test or Tests Performed: Quantitative, White Blood Cell Count (WBC), White Blood Cell Differential [LY $( \% / \# )$ , MO $( \% / \# )$ , GR $( \% / \# ) ]$ , Red Blood Cell Count (RBC), Hemoglobin (Hgb), Hematocrit (Hct), Platelet Count (Plt)

# E. System Descriptions:

1. Device Description: $\mathrm { D x H ^ { T M } } 3 0 0$ and DxH™ 300C COULTER $^ \mathrm { \textregistered }$ Cellular Analysis Analyzers are intended for In Vitro Diagnostic Use in clinical laboratories. The $\mathrm { D x H } 3 0 0 \mathrm { C }$ has the capability to process samples in an open and close vial mode of operation; the $\mathrm { D x H } 3 0 0$ only operates in an open vial mode. The DxH 300 Systems provide automated complete blood count and leukocyte differentials.

The instrument system is comprised of the analyzer and a suite of analytical reagents that allow for simultaneous quantitative determination of hematological parameters through the use of impedance and colorimetric method. Additional reagents provide system cleaning and quality control and calibration.

The system has two counting modes, whole blood and predilute mode. The difference in the two modes is the amount of sample aspirated and the amount of reagents added for the final dilution to be analyzed. The aspiration pathway and testing principle are the same.

2. Principles of Operation:

The DxH 300 Systems use the Coulter principle of impedance along with a colorimetric method for hemoglobin to determine quantitative and qualitative measurements of biological and physical properties of cells. The Coulter principle accurately counts and sizes cells by detecting and measuring changes in electrical resistance when a particle (such as a cell) in a conductive liquid passes through a small aperture. Each cell suspended in a conductive liquid (diluent) acts as an insulator. As each cell goes through the aperture it momentarily increases the resistance of the electrical path between two submerged electrodes, one located on either side of the aperture. This causes an electrical pulse that can be counted and sized. For counting, the vacuum used to pull the diluted suspension of cells through the aperture must be at a regulated volume. While the number of pulses indicates particle count, the size of the electrical pulse is proportional to the cell volume.

3. Modes of Operation: DxH™ 300 only operates in an open vial mode.

DxH™ 300C operates in an open and closed vial mode of operation.

4. Specimen Identification:

Patient sample ID (manual entry) and auto-numbering (auto-sequencing) or optional Bar-Code Scanner

5. Specimen Sampling and Handling:

The specimen is mixed by inversion and run in the either whole-blood or the predilute mode.

6. Calibration:

Calibration and verification of calibration with the use of COULTER S-CAL calibrator and COULTER LIN-X Linearity Control respectively, are performed based on the performance of the quality control program, and according to laboratory procedures and local or national regulations.

7. Quality Control:

Beckman Coulter recommends that quality control checks be performed using commercial controls at intervals established by the laboratory or as required by laboratory accreditation, licensing, or regulatory agencies.

Three levels of varying component concentrations (Abnormal Low, Abnormal High, and Normal) of the Coulter 4C-EX 300 Cell Control are offered.

8. Software:

The software is used to operate the system which features sample management, sample processing, data acquisition, data processing, result management, patient data management, and instrument management. The system is comprised of the $\mathrm { D x H } 3 0 0$ analyzer (Closed Vial configuration or Open Vial configuration) with touch screen and an electronic keyboard. The software system consists of a Main Control Processor component (including algorithm), Application Processor component (including data management), Print Processor and CD Burning Processor.

FDA has reviewed applicant’s Hazard Analysis and Software Development processes for this line of product types:

Yes____X____ or No_

# F. Regulatory Information:

1. Regulation section: 21 CFR Section 864.5220, Automated differential cell counter.

2. Classification: Class II

3 Product code: GKZ, Counter, differential cell

4. Panel: Hematology (81)

# G. Intended Use:

1. Indication(s) for Use: The DxH 300 COULTER Cellular Analysis System and the DxH 300C COULTER Cellular Analysis System are quantitative automated hematology analyzers for in vitro diagnostic use in clinical laboratories. The DxH 300 COULTER Cellular Analysis System and the DxH 300C COULTER Cellular Analysis System provide complete blood count, (WBC, RBC, HGB, HCT, MCV,

MCH, MCHC, RDW, RDW-SD, PLT, MPV) and Leukocyte 3-Part Differential [LY $( \% / \# )$ , MO $( \% / \# )$ , GR $( \% / \# ) ]$ for whole blood specimens, collected in a salt of EDTA [dipotassium (K2) or tripotassium (K3)] obtained by venipuncture, heel or fingerstick. The purpose of the DxH 300 and the DxH 300C is to identify normal human patients, with normal system-generated parameters, from patients whose results require additional studies.

2. Special Conditions for Use Statements: For Prescription Use Only

# H. Substantial Equivalence Information:

1. Predicate Device Name(s) and 510(k) numbers: COULTER $^ \mathrm { \textregistered }$ AcT Diff 2™ (k990352) COULTER $^ \mathrm { \textregistered }$ LH 780 Hematology Analyzer (k61616)   
2. Comparison with Predicate Device:

<table><tr><td colspan="6" rowspan="1">Similarities</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">DxH 300 and DxH 300C</td><td colspan="3" rowspan="1">COULTER ACT Diff 2</td><td colspan="1" rowspan="1">COULTER LH 780</td></tr><tr><td colspan="1" rowspan="3">Intended Use</td><td colspan="1" rowspan="3">The DxH 300 COULTER CellularAnalysis System and the DxH 300CCOULTER Cellular Analysis Systemare quantitative automatedhematology analyzers for in vitrodiagnostic use in clinicallaboratories. The DxH 300COULTER Cellular Analysis Systemand the DxH 300C COULTERCellular Analysis System providecomplete blood count, (WBC, RBC,HGB, HCT, MCV, MCH, MCHC,RDW, RDW-SD, PLT, MPV) andLeukocyte 3-Part Differential [LY(%/#), MO (%/#), GR (%/#)] forwhole blood specimens, collected ina salt of EDTA [dipotassium (K2) ortripotassium (K3)] obtained byvenipuncture, heel or fingerstick.The purpose of the DxH 300 and theDxH 300C is to identify normalhuman patients, with normal system-generated parameters, from patientswhose results require additionalstudies.</td><td colspan="3" rowspan="3">The COULTER ACT Diff2 analyzer is aquantitative, automatedhematology analyzer andleukocyte differentialcounter For In VitroDiagnostic Use in clinicallaboratories. The purposeis to identify the normalhuman patient, with allnormal system-generatedparameters, and to flag oridentify patient resultsthat require additionalstudies.</td><td colspan="1" rowspan="3">The COULTER LH 780Hematology Analyzer is aquantitative, automatedhematology analyzer andleukocyte differentialcounter For In VitroDiagnostic Use in clinicallaboratories. TheCOULTER LH 780Hematology Analyzerprovides automatedReticulocyte analysis andenumeration of nucleatedred blood cells (NRBCs) aswell as an automatedmethod for enumeration ofRBCs and WBCs in bodyfluids.</td></tr><tr><td colspan="1" rowspan="1">st</td></tr><tr><td colspan="2" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">SamplingMechanism</td><td colspan="1" rowspan="1">DxH 300C has manual presentationfor open or closed vial samplingwhole blood analysis and pre-dilutemode. DxH 300 does not performclosed vial sampling</td><td colspan="3" rowspan="1">Same as DxH 300C</td><td colspan="1" rowspan="1">Manual presentation foropen vial. Automatedpresentation for closed vialsampling from 12 positioncassette. Maximum loadcapacity 12 racks</td></tr><tr><td colspan="1" rowspan="1">SampleProcessing</td><td colspan="1" rowspan="1">Utilizes an automatic sampling,diluting and mixing device forsample processing</td><td colspan="3" rowspan="1">Same</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Sample ID</td><td colspan="1" rowspan="1">Manual barcode scan of sample tubeidentifier or manual keyboard entryof sample identifier. Configurable to</td><td colspan="3" rowspan="1">Mandatory sampleidentification.Configurable to auto-</td><td colspan="1" rowspan="1">Same with additionalautomated barcode read ofcassette for sample tube</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">auto-increment a 16 digitidentification number or allowmanual entry up to 16 digits.</td><td colspan="1" rowspan="1">increment 9 digitidentification number orallow manual entry of upto 14 digits.</td><td colspan="1" rowspan="1">identification,</td></tr><tr><td colspan="1" rowspan="1">WBC, RBC,MCV, Plt,</td><td colspan="1" rowspan="1">Aperture impedance</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Hgb</td><td colspan="1" rowspan="1">Spectrophotometric</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">WBCDifferential</td><td colspan="1" rowspan="1">Instrument calculates a threepopulation leukocyte count (LY%,MO%, GR %) from the WBChistogram based on cell size. Cellsbetween 35 fL and 90fL areclassified as lymphocytes, between90 fL to 160 fL are mononuclear andbetween 160 fL to 450 fL aregranulocytes. The absolute numberfor each population is thencalculated.</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">VCS Technology usingAperture impedance (DC),Conductivity (RF), LaserLight Scatter</td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Anti-coagulated whole blood in a saltof K2 or K3 EDTA</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Parameters</td><td colspan="1" rowspan="1">WBC, RBC, Hgb, Hct, MCV, MCH,MCHC, RDW, RDW-SD, Plt, MPV,LY%, MO%, GR%, LY#, MO# andGR#</td><td colspan="1" rowspan="1">Same without RDW-SD</td><td colspan="1" rowspan="1">Same CBC parameters with5-part diff [LY (%/#), MO(%/#), NE (%/#), EO (%/#),BA (%/#)], NRBC%,NRBC#, RET%, RET#, IRFand MRV.</td></tr><tr><td colspan="1" rowspan="1">Data Analysis</td><td colspan="1" rowspan="1">Analog raw data analyzed byalgorithms to generate reportedparameters.</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Data reporting</td><td colspan="1" rowspan="1">Display, printing and transmission ofdata to LIS/HIS.</td><td colspan="1" rowspan="1">Same</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">QualityControlTechniques</td><td colspan="1" rowspan="1">Daily Instruments Check,Commercial Controls, PatientControls, Inter-laboratory QualityAssurance Program (IQAP), XBAnalysis, Extended QC and XMAnalysis</td><td colspan="1" rowspan="1">Same without XBAnalysis, Extended QCand XM Analysis</td><td colspan="1" rowspan="1">Same with additional DeltaChecks</td></tr></table>

<table><tr><td colspan="4" rowspan="1">Differences</td></tr><tr><td colspan="1" rowspan="1">Item</td><td colspan="1" rowspan="1">DxH 300 and DxH 300C</td><td colspan="1" rowspan="1">COULTER ACT Diff 2</td><td colspan="1" rowspan="1">COULTER LH 780</td></tr><tr><td colspan="1" rowspan="1">Throughput forCBC/Diff</td><td colspan="1" rowspan="1">60 samples per hour</td><td colspan="1" rowspan="1">50 samples per hour</td><td colspan="1" rowspan="1">110 samples per hour</td></tr><tr><td colspan="1" rowspan="1">SamplePreparation</td><td colspan="1" rowspan="1">Syringe for sample aspiration /delivery and also for reagentdelivery</td><td colspan="1" rowspan="1">FMI (Fluid Metering,Inc.) Pumps for sampleaspiration/ delivery andalso for reagent delivery.</td><td colspan="1" rowspan="1">Rotary and linear shearvalves for bloodsegmentation. Diaphragmand displacement pumps forreagent delivery.</td></tr><tr><td colspan="1" rowspan="1">Sample aspirationVolume</td><td colspan="1" rowspan="1">17 µL. of whole blood in theClosed or Open Vial whole bloodanalysis mode 20μL of blood toprepare a prediluted sample forthe Predilute analysis mode</td><td colspan="1" rowspan="1">18 μL of whole blood inthe Closed or Open Vialwhole blood analysismode20 μL of predilutedblood in the Prediluteanalysis mode</td><td colspan="1" rowspan="1">Automatic, cap-piercing:300μLManual, open-vial mode:200μLPredilute: 200μL-customerdefined dilution ratio inrange of 1:1 to 1:5</td></tr><tr><td colspan="1" rowspan="1">Analysis Reagents</td><td colspan="1" rowspan="1">DxHTM 300 Pack-contains</td><td colspan="1" rowspan="1">COULTER®</td><td colspan="1" rowspan="1">COULTER® LH Series</td></tr><tr><td colspan="1" rowspan="1">−</td><td colspan="1" rowspan="1">COULTER® DxH Diluent(Optimized Isoton 4 Diluent)COULTER® DxH Cell Lyse(Same as Lyse S®4 lytic agent)DxH 300 Rinse</td><td colspan="1" rowspan="1">ISOTON® III DiluentCOULTER® LYSE S®III Diff Lytic Agent</td><td colspan="1" rowspan="1">DiluentCOULTER® Isoton 4DiluentCOULTER® LH Series PakCOULTER® LH SeriesRetic PakCOULTER® Lyse S® IIILytic AgentCOULTER® Lyse S® 4Lytic Agent</td></tr><tr><td colspan="1" rowspan="1">Quality Control&amp; Calibrators</td><td colspan="1" rowspan="1">COULTER® 4C EX 300 CellControlCOULTER LIN-X LinearityControlCOULTER® S-CAL® CalibratorKit</td><td colspan="1" rowspan="1">COULTER® 4C® PlusCell ControlCOULTER® 4C ESCell ControlCOULTER® S-CAL®Calibrator KitCOULTER® LIN-C®Linearity Control</td><td colspan="1" rowspan="1">COULTER® 5C® CellControlCOULTER® LatronTMPrimer and Latron ControlCOULTER® LIN-C®Linearity ControlCOULTER® S-CAL®Calibrator Kit</td></tr><tr><td colspan="1" rowspan="1">Cleaning Agents</td><td colspan="1" rowspan="1">COULTER® DxH Cleaner</td><td colspan="1" rowspan="1">COULTER® AcT RinseShutdown Diluent</td><td colspan="1" rowspan="1">COULTER® LH SeriesCleaner</td></tr></table>

# I. Special Control/Guidance Document Referenced (if applicable):

Class II Special Controls Guidance Document: Premarket Notifications for   
Automated Differential Cell Counters for Immature or Abnormal Blood Cells; Final Guidance for Industry and FDA   
CLSI EP09-A2, Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline-Second Edition   
CLSI H20-A2, Reference Leukocyte (WBC) Differential Count (Proportional) and Evaluation of Instrumental Methods; Approved Standard-Second Edition   
CLSI EP05-A2, Evaluation of Precision Performance of Quantitative Measurement Methods; Approved Guideline-Second Edition   
CLSI EP06-A, Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach; Approved Guideline   
CLSI H3-A6, Procedures for the Collection of Diagnostic Blood Specimens by Venipuncture; Approved Standard-Sixth Edition   
C28-A3, Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline-Third Edition   
CLSI H26-A2, Validation, Verification, and Quality Assurance of Automated Hematology Analyzers; Approved Standard-Second Edition

# J. Performance Characteristics:

1. Analytical Performance:

a. Accuracy:

A total of 1383 samples were tested at three (3) sites, one in Canada and two in the US. Patient demographics include age range from ${ > } 1$ month to ${ > } 6 0$ years of age, 611 females, 637 males and 135 samples with unknown age and gender. The ratio of normal to abnormal blood specimens analyzed was approximately one to one. For each whole blood sample, two manual wedge smears were prepared and stained with Wright-Giemsa stain. A 400 cell WBC differential was performed on the smears per CLSI H20-A2. The differential results from the $\mathrm { D x H } 3 0 0$ and $\mathrm { D x H } 3 0 0 \mathrm { C }$ were then compared against AcT Diff2 results and the manual smear differential results.

An estimation of the bias/difference was determined for each parameter and the DxH 300 systems met specifications at $0 . 1 0 \%$ difference limits. Whole Blood Accuracy and Regression vs Predicate (see tables below) and WBC Differential Accuracy vs Manual differential comparisons were performed. The DxH 300 systems demonstrated comparable results to the predicate devices.

DxH 300 Whole Blood Regression Results vs. Predicate   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Intercept 95%Conf. Limits</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Slope 95%Conf. Limits</td><td rowspan=1 colspan=2>Mean</td></tr><tr><td rowspan=1 colspan=1>Parameter</td><td rowspan=1 colspan=1>Units</td><td rowspan=1 colspan=1>Correlation</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>Lower</td><td rowspan=1 colspan=1>Upper</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Lower</td><td rowspan=1 colspan=1>Upper</td><td rowspan=1 colspan=1>Test</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>WBC</td><td rowspan=1 colspan=1>x103 /uL</td><td rowspan=1 colspan=1>0.998</td><td rowspan=1 colspan=1>0.184</td><td rowspan=1 colspan=1>0.105</td><td rowspan=1 colspan=1>0.262</td><td rowspan=1 colspan=1>0.974</td><td rowspan=1 colspan=1>0.971</td><td rowspan=1 colspan=1>0.978</td><td rowspan=1 colspan=1>11.2</td><td rowspan=1 colspan=1>11.3</td></tr><tr><td rowspan=1 colspan=1>RBC</td><td rowspan=1 colspan=1>x106/uL</td><td rowspan=1 colspan=1>0.994</td><td rowspan=1 colspan=1>0.028</td><td rowspan=1 colspan=1>0.002</td><td rowspan=1 colspan=1>0.053</td><td rowspan=1 colspan=1>0.993</td><td rowspan=1 colspan=1>0.986</td><td rowspan=1 colspan=1>0.999</td><td rowspan=1 colspan=1>3.84</td><td rowspan=1 colspan=1>3.84</td></tr><tr><td rowspan=1 colspan=1>HGB</td><td rowspan=1 colspan=1>g/dL</td><td rowspan=1 colspan=1>0.996</td><td rowspan=1 colspan=1>0.030</td><td rowspan=1 colspan=1>-0.034</td><td rowspan=1 colspan=1>0.094</td><td rowspan=1 colspan=1>0.993</td><td rowspan=1 colspan=1>0.988</td><td rowspan=1 colspan=1>0.998</td><td rowspan=1 colspan=1>11.6</td><td rowspan=1 colspan=1>11.7</td></tr><tr><td rowspan=1 colspan=1>MCV</td><td rowspan=1 colspan=1>fL</td><td rowspan=1 colspan=1>0.989</td><td rowspan=1 colspan=1>-2.123</td><td rowspan=1 colspan=1>-2.916</td><td rowspan=1 colspan=1>-1.331</td><td rowspan=1 colspan=1>1.033</td><td rowspan=1 colspan=1>1.025</td><td rowspan=1 colspan=1>1.042</td><td rowspan=1 colspan=1>91.2</td><td rowspan=1 colspan=1>90.4</td></tr><tr><td rowspan=1 colspan=1>RDW</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>0.978</td><td rowspan=1 colspan=1>0.644</td><td rowspan=1 colspan=1>0.458</td><td rowspan=1 colspan=1>0.830</td><td rowspan=1 colspan=1>0.980</td><td rowspan=1 colspan=1>0.968</td><td rowspan=1 colspan=1>0.993</td><td rowspan=1 colspan=1>15.2</td><td rowspan=1 colspan=1>14.9</td></tr><tr><td rowspan=1 colspan=1>RDW-SD</td><td rowspan=1 colspan=1>fL</td><td rowspan=1 colspan=1>0.967</td><td rowspan=1 colspan=1>-0.201</td><td rowspan=1 colspan=1>-0.974</td><td rowspan=1 colspan=1>0.571</td><td rowspan=1 colspan=1>1.027</td><td rowspan=1 colspan=1>1.011</td><td rowspan=1 colspan=1>1.042</td><td rowspan=1 colspan=1>49.2</td><td rowspan=1 colspan=1>48.1</td></tr><tr><td rowspan=1 colspan=1>PLT</td><td rowspan=1 colspan=1>x10^3 /uL</td><td rowspan=1 colspan=1>0.996</td><td rowspan=1 colspan=1>2.319</td><td rowspan=1 colspan=1>0.718</td><td rowspan=1 colspan=1>3.919</td><td rowspan=1 colspan=1>0.989</td><td rowspan=1 colspan=1>0.984</td><td rowspan=1 colspan=1>0.995</td><td rowspan=1 colspan=1>246</td><td rowspan=1 colspan=1>246</td></tr><tr><td rowspan=1 colspan=1>MPV</td><td rowspan=1 colspan=1>fL</td><td rowspan=1 colspan=1>0.853</td><td rowspan=1 colspan=1>2.209</td><td rowspan=1 colspan=1>1.975</td><td rowspan=1 colspan=1>2.443</td><td rowspan=1 colspan=1>0.732</td><td rowspan=1 colspan=1>0.704</td><td rowspan=1 colspan=1>0.761</td><td rowspan=1 colspan=1>8.2</td><td rowspan=1 colspan=1>8.2</td></tr><tr><td rowspan=1 colspan=1>GR</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>0.983</td><td rowspan=1 colspan=1>-3.265</td><td rowspan=1 colspan=1>-4.174</td><td rowspan=1 colspan=1>-2.357</td><td rowspan=1 colspan=1>1.043</td><td rowspan=1 colspan=1>1.029</td><td rowspan=1 colspan=1>1.056</td><td rowspan=1 colspan=1>64.8</td><td rowspan=1 colspan=1>65.3</td></tr><tr><td rowspan=1 colspan=1>LY</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>0.990</td><td rowspan=1 colspan=1>-1.795</td><td rowspan=1 colspan=1>-2.119</td><td rowspan=1 colspan=1>-1.472</td><td rowspan=1 colspan=1>1.061</td><td rowspan=1 colspan=1>1.050</td><td rowspan=1 colspan=1>1.072</td><td rowspan=1 colspan=1>27.7</td><td rowspan=1 colspan=1>27.8</td></tr><tr><td rowspan=1 colspan=1>MO</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>0.658</td><td rowspan=1 colspan=1>2.847</td><td rowspan=1 colspan=1>2.493</td><td rowspan=1 colspan=1>3.201</td><td rowspan=1 colspan=1>0.639</td><td rowspan=1 colspan=1>0.587</td><td rowspan=1 colspan=1>0.691</td><td rowspan=1 colspan=1>7.0</td><td rowspan=1 colspan=1>6.4</td></tr></table>

DxH 300C Whole Blood Regression Results vs. Predicate   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Intercept 95%Conf. Limits</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Slope 95%Conf. Limits</td><td rowspan=1 colspan=2>Mean</td></tr><tr><td rowspan=1 colspan=1>Parameter</td><td rowspan=1 colspan=1>Units</td><td rowspan=1 colspan=1>Correlation</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>Lower</td><td rowspan=1 colspan=1>Upper</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Lower</td><td rowspan=1 colspan=1>Upper</td><td rowspan=1 colspan=1>Test</td><td rowspan=1 colspan=1>Predicate</td></tr><tr><td rowspan=1 colspan=1>WBC</td><td rowspan=1 colspan=1>x103/uL</td><td rowspan=1 colspan=1>0.998</td><td rowspan=1 colspan=1>0.105</td><td rowspan=1 colspan=1>0.026</td><td rowspan=1 colspan=1>0.185</td><td rowspan=1 colspan=1>0.970</td><td rowspan=1 colspan=1>0.967</td><td rowspan=1 colspan=1>0.974</td><td rowspan=1 colspan=1>11.0</td><td rowspan=1 colspan=1>11.2</td></tr><tr><td rowspan=1 colspan=1>RBC</td><td rowspan=1 colspan=1>x106/uL</td><td rowspan=1 colspan=1>0.992</td><td rowspan=1 colspan=1>0.015</td><td rowspan=1 colspan=1>-0.013</td><td rowspan=1 colspan=1>0.043</td><td rowspan=1 colspan=1>0.993</td><td rowspan=1 colspan=1>0.986</td><td rowspan=1 colspan=1>1.000</td><td rowspan=1 colspan=1>3.82</td><td rowspan=1 colspan=1>3.83</td></tr><tr><td rowspan=1 colspan=1>HGB</td><td rowspan=1 colspan=1>g/dL</td><td rowspan=1 colspan=1>0.997</td><td rowspan=1 colspan=1>-0.031</td><td rowspan=1 colspan=1>-0.088</td><td rowspan=1 colspan=1>0.026</td><td rowspan=1 colspan=1>1.003</td><td rowspan=1 colspan=1>0.998</td><td rowspan=1 colspan=1>1.008</td><td rowspan=1 colspan=1>11.7</td><td rowspan=1 colspan=1>11.7</td></tr><tr><td rowspan=1 colspan=1>MCV</td><td rowspan=1 colspan=1>fL</td><td rowspan=1 colspan=1>0.989</td><td rowspan=1 colspan=1>-1.818</td><td rowspan=1 colspan=1>-2.597</td><td rowspan=1 colspan=1>-1.040</td><td rowspan=1 colspan=1>1.026</td><td rowspan=1 colspan=1>1.018</td><td rowspan=1 colspan=1>1.035</td><td rowspan=1 colspan=1>91.0</td><td rowspan=1 colspan=1>90.4</td></tr><tr><td rowspan=1 colspan=1>RDW</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>0.978</td><td rowspan=1 colspan=1>0.707</td><td rowspan=1 colspan=1>0.521</td><td rowspan=1 colspan=1>0.894</td><td rowspan=1 colspan=1>0.972</td><td rowspan=1 colspan=1>0.959</td><td rowspan=1 colspan=1>0.984</td><td rowspan=1 colspan=1>15.2</td><td rowspan=1 colspan=1>14.9</td></tr><tr><td rowspan=1 colspan=1>RDW-SD</td><td rowspan=1 colspan=1>fL</td><td rowspan=1 colspan=1>0.967</td><td rowspan=1 colspan=1>0.014</td><td rowspan=1 colspan=1>-0.770</td><td rowspan=1 colspan=1>0.798</td><td rowspan=1 colspan=1>1.030</td><td rowspan=1 colspan=1>1.014</td><td rowspan=1 colspan=1>1.046</td><td rowspan=1 colspan=1>49.6</td><td rowspan=1 colspan=1>48.1</td></tr><tr><td rowspan=1 colspan=1>PLT</td><td rowspan=1 colspan=1>x103 /uL</td><td rowspan=1 colspan=1>0.996</td><td rowspan=1 colspan=1>1.590</td><td rowspan=1 colspan=1>-0.005</td><td rowspan=1 colspan=1>3.184</td><td rowspan=1 colspan=1>0.959</td><td rowspan=1 colspan=1>0.954</td><td rowspan=1 colspan=1>0.964</td><td rowspan=1 colspan=1>237</td><td rowspan=1 colspan=1>245</td></tr><tr><td rowspan=1 colspan=1>MPV</td><td rowspan=1 colspan=1>fL</td><td rowspan=1 colspan=1>0.854</td><td rowspan=1 colspan=1>2.146</td><td rowspan=1 colspan=1>1.905</td><td rowspan=1 colspan=1>2.386</td><td rowspan=1 colspan=1>0.750</td><td rowspan=1 colspan=1>0.721</td><td rowspan=1 colspan=1>0.780</td><td rowspan=1 colspan=1>8.3</td><td rowspan=1 colspan=1>8.2</td></tr><tr><td rowspan=1 colspan=1>GR</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>0.983</td><td rowspan=1 colspan=1>-2.934</td><td rowspan=1 colspan=1>-3.855</td><td rowspan=1 colspan=1>-2.014</td><td rowspan=1 colspan=1>1.039</td><td rowspan=1 colspan=1>1.025</td><td rowspan=1 colspan=1>1.053</td><td rowspan=1 colspan=1>64.8</td><td rowspan=1 colspan=1>65.2</td></tr><tr><td rowspan=1 colspan=1>LY</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>0.988</td><td rowspan=1 colspan=1>-1.676</td><td rowspan=1 colspan=1>-2.023</td><td rowspan=1 colspan=1>-1.329</td><td rowspan=1 colspan=1>1.059</td><td rowspan=1 colspan=1>1.047</td><td rowspan=1 colspan=1>1.070</td><td rowspan=1 colspan=1>27.8</td><td rowspan=1 colspan=1>27.8</td></tr><tr><td rowspan=1 colspan=1>MO</td><td rowspan=1 colspan=1>%</td><td rowspan=1 colspan=1>0.673</td><td rowspan=1 colspan=1>2.701</td><td rowspan=1 colspan=1>2.358</td><td rowspan=1 colspan=1>3.044</td><td rowspan=1 colspan=1>0.642</td><td rowspan=1 colspan=1>0.591</td><td rowspan=1 colspan=1>0.692</td><td rowspan=1 colspan=1>6.8</td><td rowspan=1 colspan=1>6.4</td></tr></table>

# $b$ . Precision/Reproducibility:

To evaluate the Complete Blood Count (CBC) and Leukocyte 3 Part Differential (Diff), three levels of control material (4C-ES Cell Control Low, Normal and High) were run in duplicate twice each day for a minimum of 20 days on the $\mathrm { D x H } 3 0 0$ and $\mathrm { D x H } 3 0 0 \mathrm { C }$ analyzers at each of the three test sites. The results were analyzed according to the guidance provided in CLSI EP05- A2 and met the acceptance criteria as displayed in the tables below.

4C-ES Cell Control DxH 300   

<table><tr><td rowspan=1 colspan=1>Parameter</td><td rowspan=1 colspan=2>Normal4C-ES</td><td rowspan=1 colspan=2>Abnormal Low4C-ES</td><td rowspan=1 colspan=2>Abnormal High4C-ES</td><td rowspan=1 colspan=1>AcceptanceCriteria</td></tr><tr><td rowspan=1 colspan=1>N=</td><td rowspan=1 colspan=2>265</td><td rowspan=1 colspan=2>270</td><td rowspan=1 colspan=2>272</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>CV%/SD</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>CV%/SD</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>CV%/SD</td><td rowspan=1 colspan=1>Mean</td></tr><tr><td rowspan=1 colspan=1>WBC</td><td rowspan=1 colspan=1>8.7</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>18.0</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>≤ 3.0% CV</td></tr><tr><td rowspan=1 colspan=1>RBC</td><td rowspan=1 colspan=1>4.19</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>2.49</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>5.33</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>≤ 2.0% CV</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>12.9</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>6.8</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>18.2</td><td rowspan=1 colspan=1>0.4%</td><td rowspan=1 colspan=1>≤ 1.5% CV</td></tr><tr><td rowspan=1 colspan=1>MCV</td><td rowspan=1 colspan=1>88.3</td><td rowspan=1 colspan=1>0.14%</td><td rowspan=1 colspan=1>79.1</td><td rowspan=1 colspan=1>0.22%</td><td rowspan=1 colspan=1>96.7</td><td rowspan=1 colspan=1>0.17%</td><td rowspan=1 colspan=1>≤ 1.0% CV</td></tr><tr><td rowspan=1 colspan=1>Platelet</td><td rowspan=1 colspan=1>227</td><td rowspan=1 colspan=1>2.9%</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>4.1%</td><td rowspan=1 colspan=1>443</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>≤ 5.0% CV</td></tr><tr><td rowspan=1 colspan=1>MPV</td><td rowspan=1 colspan=1>10.3</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>9.9</td><td rowspan=1 colspan=1>2.8%</td><td rowspan=1 colspan=1>10.3</td><td rowspan=1 colspan=1>0.7%</td><td rowspan=1 colspan=1>≤ 3.0% CV</td></tr><tr><td rowspan=1 colspan=1>RDW</td><td rowspan=1 colspan=1>12.0</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>13.7</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>11.7</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>≤ 3.5% CV</td></tr><tr><td rowspan=1 colspan=1>RDW-SD</td><td rowspan=1 colspan=1>41.4</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>40.3</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>44.1</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>≤ 3.5% CV</td></tr><tr><td rowspan=1 colspan=1>Granulocyte %</td><td rowspan=1 colspan=1>41.3</td><td rowspan=1 colspan=1>0.07 SD</td><td rowspan=1 colspan=1>53.1</td><td rowspan=1 colspan=1>0.05 SD</td><td rowspan=1 colspan=1>33.7</td><td rowspan=1 colspan=1>0.08 SD</td><td rowspan=1 colspan=1>≤ 3.0 SD</td></tr><tr><td rowspan=1 colspan=1>Lymphocyte %</td><td rowspan=1 colspan=1>45.9</td><td rowspan=1 colspan=1>0.12 SD</td><td rowspan=1 colspan=1>34.5</td><td rowspan=1 colspan=1>0.08 SD</td><td rowspan=1 colspan=1>50.6</td><td rowspan=1 colspan=1>0.15 SD</td><td rowspan=1 colspan=1>≤ 1.5 SD</td></tr><tr><td rowspan=1 colspan=1>Mononuclear%</td><td rowspan=1 colspan=1>12.8</td><td rowspan=1 colspan=1>0.03 SD</td><td rowspan=1 colspan=1>12.4</td><td rowspan=1 colspan=1>0.02 SD</td><td rowspan=1 colspan=1>15.7</td><td rowspan=1 colspan=1>0.04 SD</td><td rowspan=1 colspan=1>≤ 1.5 SD</td></tr></table>

4C-ES Cell Control DxH 300C   

<table><tr><td rowspan=1 colspan=1>Parameter</td><td rowspan=1 colspan=2>Normal 4C-ES</td><td rowspan=1 colspan=2>Abnormal Low4C-ES</td><td rowspan=1 colspan=2>Abnormal High4C-ES</td><td rowspan=1 colspan=1>AcceptanceCriteria</td></tr><tr><td rowspan=1 colspan=1>N=</td><td rowspan=1 colspan=2>272</td><td rowspan=1 colspan=2>270</td><td rowspan=1 colspan=2>270</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>CV%/SD</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>CV%/SD</td><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>CV%/SD</td><td rowspan=1 colspan=1>Mean</td></tr><tr><td rowspan=1 colspan=1>WBC</td><td rowspan=1 colspan=1>8.7</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>18.0</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>≤ 3.0% CV</td></tr><tr><td rowspan=1 colspan=1>RBC</td><td rowspan=1 colspan=1>4.17</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>2.50</td><td rowspan=1 colspan=1>0.9%</td><td rowspan=1 colspan=1>5.35</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>≤ 2.0% CV</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>12.9</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>6.8</td><td rowspan=1 colspan=1>0.7%</td><td rowspan=1 colspan=1>18.3</td><td rowspan=1 colspan=1>0.5%</td><td rowspan=1 colspan=1>≤ 1.5% CV</td></tr><tr><td rowspan=1 colspan=1>MCV</td><td rowspan=1 colspan=1>88.2</td><td rowspan=1 colspan=1>0.09%</td><td rowspan=1 colspan=1>79.1</td><td rowspan=1 colspan=1>0.19%</td><td rowspan=1 colspan=1>96.7</td><td rowspan=1 colspan=1>0.04%</td><td rowspan=1 colspan=1>≤ 1.0% CV</td></tr><tr><td rowspan=1 colspan=1>Platelet</td><td rowspan=1 colspan=1>223</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>77</td><td rowspan=1 colspan=1>4.4%</td><td rowspan=1 colspan=1>435</td><td rowspan=1 colspan=1>1.5%</td><td rowspan=1 colspan=1>≤ 5.0% CV</td></tr><tr><td rowspan=1 colspan=1>MPV</td><td rowspan=1 colspan=1>10.3</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>9.9</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>10.3</td><td rowspan=1 colspan=1>0.7%</td><td rowspan=1 colspan=1>≤ 3.0% CV</td></tr><tr><td rowspan=1 colspan=1>RDW</td><td rowspan=1 colspan=1>12.0</td><td rowspan=1 colspan=1>1.1%</td><td rowspan=1 colspan=1>13.7</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>11.6</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>≤ 3.5% CV</td></tr><tr><td rowspan=1 colspan=1>RDW-SD</td><td rowspan=1 colspan=1>41.6</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>40.7</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>44.2</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>≤ 3.5% CV</td></tr><tr><td rowspan=1 colspan=1>Granulocyte %</td><td rowspan=1 colspan=1>41.5</td><td rowspan=1 colspan=1>0.10 SD</td><td rowspan=1 colspan=1>53.2</td><td rowspan=1 colspan=1>0.05 SD</td><td rowspan=1 colspan=1>33.7</td><td rowspan=1 colspan=1>0.10 SD</td><td rowspan=1 colspan=1>≤ 3.0 SD</td></tr><tr><td rowspan=1 colspan=1>Lymphocyte %</td><td rowspan=1 colspan=1>45.8</td><td rowspan=1 colspan=1>0.12 SD</td><td rowspan=1 colspan=1>34.2</td><td rowspan=1 colspan=1>0.07 SD</td><td rowspan=1 colspan=1>50.5</td><td rowspan=1 colspan=1>0.16 SD</td><td rowspan=1 colspan=1>≤ 1.5 SD</td></tr><tr><td rowspan=1 colspan=1>Mononuclear%</td><td rowspan=1 colspan=1>12.8</td><td rowspan=1 colspan=1>0.02 SD</td><td rowspan=1 colspan=1>12.5</td><td rowspan=1 colspan=1>0.02 SD</td><td rowspan=1 colspan=1>15.7</td><td rowspan=1 colspan=1>0.04 SD</td><td rowspan=1 colspan=1>≤ 1.5 SD</td></tr></table>

# With-In Run Repeatability Study

To substantiate the product labeling claim of with-in run repeatability as a coefficient of variation from replicates of a single sample, ten replicates of a single normal whole blood specimen were tested on both the $\mathrm { D x H } 3 0 0$ and DxH 300C analyzers. The results and specifications are shown in the table below.

$\mathbf { N = } \mathbf { 1 0 }$ Repeatability   

<table><tr><td colspan="1" rowspan="1">Parameter</td><td colspan="1" rowspan="1">Units</td><td colspan="2" rowspan="1">DxH 300</td><td colspan="2" rowspan="1">DXH 300C</td><td colspan="2" rowspan="1">Specifications</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">Mean</td><td colspan="1" rowspan="1">CV%/SD</td><td colspan="1" rowspan="1">Mean</td><td colspan="1" rowspan="1">CV%/SD</td><td colspan="1" rowspan="1">Range</td><td colspan="1" rowspan="1">CV% orSD</td></tr><tr><td colspan="1" rowspan="1">WBC</td><td colspan="1" rowspan="1">103/μL</td><td colspan="1" rowspan="1">6.6</td><td colspan="1" rowspan="1">1.23%</td><td colspan="1" rowspan="1">8.9</td><td colspan="1" rowspan="1">1.24%</td><td colspan="1" rowspan="1">6.0- 15.0</td><td colspan="1" rowspan="1">≤ 3.0% CV</td></tr><tr><td colspan="1" rowspan="1">RBC</td><td colspan="1" rowspan="1">10b / μL</td><td colspan="1" rowspan="1">4.24</td><td colspan="1" rowspan="1">0.60%</td><td colspan="1" rowspan="1">4.71</td><td colspan="1" rowspan="1">0.63%</td><td colspan="1" rowspan="1">3.50-6.00</td><td colspan="1" rowspan="1">≤ 2.0% CV</td></tr><tr><td colspan="1" rowspan="1">Hemoglobin</td><td colspan="1" rowspan="1">g/dL</td><td colspan="1" rowspan="1">12.6</td><td colspan="1" rowspan="1">0.22%</td><td colspan="1" rowspan="1">13.8</td><td colspan="1" rowspan="1">0.69%</td><td colspan="1" rowspan="1">11.0- 18.0</td><td colspan="1" rowspan="1">≤ 1.5% CV</td></tr><tr><td colspan="1" rowspan="1">MCV</td><td colspan="1" rowspan="1">fL</td><td colspan="1" rowspan="1">87.5</td><td colspan="1" rowspan="1">0.36%</td><td colspan="1" rowspan="1">84.7</td><td colspan="1" rowspan="1">0.53%</td><td colspan="1" rowspan="1">80.0-110.0</td><td colspan="1" rowspan="1">≤ 1.0% CV</td></tr><tr><td colspan="1" rowspan="1">Platelet</td><td colspan="1" rowspan="1">103/μL</td><td colspan="1" rowspan="1">171</td><td colspan="1" rowspan="1">4.15%</td><td colspan="1" rowspan="1">312</td><td colspan="1" rowspan="1">3.83%</td><td colspan="1" rowspan="1">150-500</td><td colspan="1" rowspan="1">≤ 5.0% CV</td></tr><tr><td colspan="1" rowspan="1">MPV</td><td colspan="1" rowspan="1">fL</td><td colspan="1" rowspan="1">9.5</td><td colspan="1" rowspan="1">2.31%</td><td colspan="1" rowspan="1">8.3</td><td colspan="1" rowspan="1">1.07%</td><td colspan="1" rowspan="1">8.0-10.0</td><td colspan="1" rowspan="1">≤ 3.0% CV</td></tr><tr><td colspan="1" rowspan="1">RDW</td><td colspan="1" rowspan="1">%</td><td colspan="1" rowspan="1">13.3</td><td colspan="1" rowspan="1">1.40%</td><td colspan="1" rowspan="1">12.5</td><td colspan="1" rowspan="1">1.51%</td><td colspan="1" rowspan="1">12.0-15.0</td><td colspan="1" rowspan="1">≤ 3.5% CV</td></tr><tr><td colspan="1" rowspan="1">RDW-SD</td><td colspan="1" rowspan="1">fL</td><td colspan="1" rowspan="1">42.1</td><td colspan="1" rowspan="1">1.20%</td><td colspan="1" rowspan="1">38.5</td><td colspan="1" rowspan="1">1.31%</td><td colspan="1" rowspan="1">33.0-48.0</td><td colspan="1" rowspan="1">≤ 3.5% CV</td></tr><tr><td colspan="1" rowspan="1">Granulocyte%</td><td colspan="1" rowspan="1">%</td><td colspan="1" rowspan="1">56.0</td><td colspan="1" rowspan="1">0.7 SD</td><td colspan="1" rowspan="1">53.3</td><td colspan="1" rowspan="1">0.8 SD</td><td colspan="1" rowspan="1">30.0-60.0</td><td colspan="1" rowspan="1">≤ 3.0 SD</td></tr><tr><td colspan="1" rowspan="1">Lymphocyte%</td><td colspan="1" rowspan="1">%</td><td colspan="1" rowspan="1">36.1</td><td colspan="1" rowspan="1">0.9 SD</td><td colspan="1" rowspan="1">40.3</td><td colspan="1" rowspan="1">0.4 SD</td><td colspan="1" rowspan="1">20.0-50.0</td><td colspan="1" rowspan="1">≤ 1.5 SD</td></tr><tr><td colspan="1" rowspan="1">Mononuclear%</td><td colspan="1" rowspan="1">%</td><td colspan="1" rowspan="1">8.0</td><td colspan="1" rowspan="1">0.6 SD</td><td colspan="1" rowspan="1">6.3</td><td colspan="1" rowspan="1">0.5 SD</td><td colspan="1" rowspan="1">2.0-10.0</td><td colspan="1" rowspan="1">≤ 1.5 SD</td></tr></table>

To demonstrate sample results are repeatable at both the upper and lower ends of the device’s measuring range, concentrations that span a significant portion of the measuring range were selected inclusive of representative samples within the medical decision levels. Repeatability was evaluated based on ten consecutive runs $( \mathrm { n } { = } 1 0 )$ for each sample for a total of 5780 runs. Repeatability was estimated as the coefficient of variation $( \mathrm { C V \% } )$ or the standard deviation (SD) of the ten runs. The values of $C V \%$ and SD for each sample were within specifications.

# c. Linearity:

WBC and Platelet linearity were performed using dilutions prepared from WBC monologs and Platelet analogs respectively. RBC and Hemoglobin linearity were performed using dilutions prepared from fresh whole blood. The whole blood was concentrated to obtain specimens to test the high linearity limit. Serial dilutions using the whole blood plasma for RBC and Hemoglobin and 4C media for WBC and Platelet were then prepared to create 10 subsequent dilutions. The mean of multiple measurements, 5 (five), from each of the 10 dilutions across the linearity range were used. Acceptable performance is indicated by the data fitting a linear regression line with a coefficient of determination (R²) of ${ > } 0 . 9 5$ and the parameters measured recovering within the bias limits. Based on CLSI EP06-A, the $\mathrm { D x H } 3 0 0$ systems demonstrated acceptable linearity results.

Summary of the recovered linearity specification and the R2 values for each parameter are displayed in the table below.

Summary of Linearity R2 Values and Specifications   

<table><tr><td rowspan=1 colspan=1>Parameter</td><td rowspan=1 colspan=1>DxH 300R2</td><td rowspan=1 colspan=1>DxH 300CR2</td><td rowspan=1 colspan=1>Bias</td><td rowspan=1 colspan=1>R2</td></tr><tr><td rowspan=1 colspan=1>WBC 0.3-100 x 103 cells/ μL</td><td rowspan=1 colspan=1>0.9999</td><td rowspan=1 colspan=1>0.9999</td><td rowspan=1 colspan=1>+/- 0.3 or 5.0%</td><td rowspan=1 colspan=1>&gt;0.95</td></tr><tr><td rowspan=1 colspan=1>WBC &gt;100-200 x 103 cells/μL</td><td rowspan=1 colspan=1>0.9979</td><td rowspan=1 colspan=1>0.9969</td><td rowspan=1 colspan=1>+/-9.0%</td><td rowspan=1 colspan=1>&gt; 0.95</td></tr><tr><td rowspan=1 colspan=1>RBC 0.2-8.00 x 106 cells/ μL</td><td rowspan=1 colspan=1>0.9997</td><td rowspan=1 colspan=1>0.9993</td><td rowspan=1 colspan=1>+/- 0.05 or 5.0%</td><td rowspan=1 colspan=1>&gt; 0.95</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin 1.0-25.0 g/dL</td><td rowspan=1 colspan=1>0.9991</td><td rowspan=1 colspan=1>0.9993</td><td rowspan=1 colspan=1>+/- 0.2 or 3.0%</td><td rowspan=1 colspan=1>&gt;0.95</td></tr><tr><td rowspan=1 colspan=1>Platelets 5-2000 x 103 cells/μL</td><td rowspan=1 colspan=1>0.9997</td><td rowspan=1 colspan=1>0.9994</td><td rowspan=1 colspan=1>+/- 10.0 or10.0%</td><td rowspan=1 colspan=1>&gt; 0.95</td></tr></table>

d. Carryover:

Carryover was determined for WBC, RBC, Hemoglobin and Platelet. Testing was performed in the analytical cycle combinations of within mode for whole blood, within mode for predilute and mode to mode. For each analytical cycle combination, triplicate sampling from a patient whole blood with extremely elevated blood components (high sample) was followed by triplicate blank samples (diluent) regarded as background level or zero carry-over with each test performed three times. For whole blood and predilute sampling, within mode and mode to mode for sampling carryover were calculated for both the $\mathrm { D x H } 3 0 0$ and DxH 300C and results were within specifications (≤ 0.5) for WBC, RBC and Hemoglobin and (≤ 1.0) for Platelets.

# e. Interfering Substances:

The accuracy studies performed on the $\mathrm { D x H } 3 0 0$ and $\mathrm { D x H } 3 0 0 \mathrm { C }$ included samples with the known interfering substances listed in the table below. Parameter flagging was observed when the interference impacted the results. Samples that did not flag achieved the accurate results for each parameter when compared to the reference.

Interfering Substances   

<table><tr><td rowspan=1 colspan=1>Parameter</td><td rowspan=1 colspan=1>Interferences</td></tr><tr><td rowspan=1 colspan=1>WBC</td><td rowspan=1 colspan=1>Lyse Resistant RBCsPlatelet ClumpsGiant PlateletsSmall LymphocytesNRBC</td></tr><tr><td rowspan=1 colspan=1>Hgb</td><td rowspan=1 colspan=1>• WBC &gt; 50 x 103 μLLyse Resistant RBCsSevere Lipemia</td></tr><tr><td rowspan=1 colspan=1>WBC Differential</td><td rowspan=1 colspan=1>Lyse Resistant RBCs</td></tr><tr><td rowspan=1 colspan=1>MCV</td><td rowspan=1 colspan=1>• WBC &gt; 140 x 10³3 μLPlatelet ClumpsGiant Platelets (High Concentration)</td></tr><tr><td rowspan=1 colspan=1>PLT</td><td rowspan=1 colspan=1>•Microcytic RBCsPlatelet ClumpsGiant Platelets</td></tr></table>

2. Other Supportive Instrument Performance Data Not Covered Above: Based on CLSI H3-A6, Procedures for the Collection of Diagnostic Blood Specimens by Venipuncture; Approved Standard-Sixth Edition, studies were designed and conducted to support claims and attributes for whole blood sampling. They were designed to evaluate the following:

a. Comparison of Venous and Capillary Blood: Specimens were collected from normal donors by capillary method according to the manufacturers recommended volume and venous collection tube in a $5 0 / 5 0 \mathrm { m i x }$ of K2 and K3 EDTA anticoagulants. One replicate of each specimen was analyzed due to volume constraints (when possible, two replicates were analyzed). This testing demonstrated venous blood presented in a standard collection tube when compared to venous blood presented in a micro collection device, the performance characteristics of the two specimen types are comparable.

b. Comparison of Open and Closed vial sampling:

Specimens from normal donors were analyzed cap-off in open vial sampling mode and compared to cap on from the closed vial sampling mode results on the DxH 300C. Samples were collected in K3 EDTA anticoagulant and analyzed in duplicate. The testing demonstrated that the DxH 300C will process the specimen in the same manner regardless of the method of sample presentation.

c. Comparison of Whole Blood Mode and Predilute Mode: Specimens from normal donors collected in a $5 0 / 5 0 \mathrm { m i x }$ of K2 and K3 EDTA anticoagulants were processed in both modes and analyzed in duplicate. The predilute sample was prepared by the user dispensing $0 . 3 8 \mathrm { m l }$ of diluent from the analyzer into an empty tube or receptacle and adding $2 0 \mu \mathrm { L }$ of whole blood then mixing the blood/diluent mixture consistent with the instructions for use provided in the proposed labeling. The testing demonstrated that the $\mathrm { D x H } 3 0 0$ and $\mathrm { D x H } 3 0 0 \mathrm { C }$ analyzers will process the specimen in the same manner regardless of the method of sampling mode.

d. Sample Stability and Storage:

Whole blood and Pre-dilute whole blood stability studies were performed. Specimens were collected in a $5 0 / 5 0 \mathrm { m i x }$ of K2 EDTA and K3 EDTA anticoagulants with stability measured using non-flagged, morphologically normal samples. Ten donors were analyzed in duplicate for each study. When samples are stored for the durations defined at controlled room temperature $[ 6 4 - 7 9 ^ { \circ }$ F $( 1 8 - 2 6 ^ { \circ } \mathrm { C } ) ]$ or at refrigerated temperature [35.6- $4 6 . 4 ^ { \circ } \mathrm { ~ F ~ }$ $\left( 2 { - } 8 ^ { \circ } \thinspace \mathrm { C } \right) ]$ the instrument results met the acceptance criteria. Whole blood stability is 24 hours at refrigerated temperature and 12 hours at room temperature. Pre-dilute whole blood stability is 30 minutes for CBC parameters and 10 minutes for Differential parameters.

e. Clinical Sensitivity and Specificity: The results of studies from 3 sites were combined. The clinical sensitivity and specificity for the $\mathrm { D x H } 3 0 0$ Systems and the AcT Diff 2 predicate instrument as compared with the manual differential for the same population of samples is shown below.

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>DxH 300</td><td rowspan=1 colspan=1>DxH 300C</td><td rowspan=1 colspan=1>Act Diff2</td></tr><tr><td rowspan=1 colspan=1>True Positive</td><td rowspan=1 colspan=1>119</td><td rowspan=1 colspan=1>122</td><td rowspan=1 colspan=1>140</td></tr><tr><td rowspan=1 colspan=1>True Negative</td><td rowspan=1 colspan=1>743</td><td rowspan=1 colspan=1>760</td><td rowspan=1 colspan=1>556</td></tr><tr><td rowspan=1 colspan=1>False Positive</td><td rowspan=1 colspan=1>165</td><td rowspan=1 colspan=1>148</td><td rowspan=1 colspan=1>352</td></tr><tr><td rowspan=1 colspan=1>False Negative</td><td rowspan=1 colspan=1>74</td><td rowspan=1 colspan=1>71</td><td rowspan=1 colspan=1>53</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>1101</td><td rowspan=1 colspan=1>1101</td><td rowspan=1 colspan=1>1101</td></tr><tr><td rowspan=1 colspan=1>Sensitivity (TP %)</td><td rowspan=1 colspan=1>61.66%</td><td rowspan=1 colspan=1>63.21%</td><td rowspan=1 colspan=1>72.54%</td></tr><tr><td rowspan=1 colspan=1>Specificity (TN %)</td><td rowspan=1 colspan=1>81.83%</td><td rowspan=1 colspan=1>83.70%</td><td rowspan=1 colspan=1>61.23%</td></tr><tr><td rowspan=1 colspan=1>Efficiency</td><td rowspan=1 colspan=1>78.29%</td><td rowspan=1 colspan=1>80.11%</td><td rowspan=1 colspan=1>63.22%</td></tr></table>

The flagging rate for the $\mathrm { D x H } 3 0 0$ Systems and the AcT Diff 2 predicate instrument as compared to the WBC manual differential for the same population of samples is shown below:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>DxH 300</td><td rowspan=1 colspan=1>DxH 300C</td><td rowspan=1 colspan=1>Act Diff2</td></tr><tr><td rowspan=1 colspan=1>% False Positive</td><td rowspan=1 colspan=1>14.99%</td><td rowspan=1 colspan=1>13.44%</td><td rowspan=1 colspan=1>31.97%</td></tr><tr><td rowspan=1 colspan=1>% False Negative</td><td rowspan=1 colspan=1>6.72%</td><td rowspan=1 colspan=1>6.45%</td><td rowspan=1 colspan=1>4.81%</td></tr></table>

f. Reference Range

A study was conducted to assess the Adult Reference Ranges for the both DxH 300 and $\mathrm { D x H } 3 0 0 \mathrm { C }$ systems using whole blood samples collected from 246 donors from the Beckman Coulter in-house blood donor program. In the study 121 male donors between the ages of 20-73 years old and 125 female donors between the ages of 19-73 were included. The non-parametric method and $9 5 \%$ confidence were used to calculate the lower and upper limits of the reference range with the priori direct sampling technique utilized.

It is recommended that laboratories establish their own ranges based on their current patient population.

# K. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# L. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.